Ovid Therapeutics Inc. - Common Stock — Quarterly Cash Flow (NASDAQ:OVID) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 81.65 M77.43 M63.85 M150.93 M225.63 M Total liabilities 22.38 M21.64 M19.15 M20.27 M27.36 M Total equity 59.28 M55.79 M44.7 M130.66 M198.27 M Total liabilities & shareholders' equities 81.65 M77.43 M63.85 M150.93 M225.63 M Total debt ————— Net debt —————

News

Ovid Therapeutics Stock: Risk-Adjusted Valuation Shows Deep Discount Despite 700% Rally

Ovid Therapeutics: Buy Next-Gen GABA-Aminotransferase Inhibitor OV329, TSC/IS Expansions

Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript

3 Best Stocks to Buy Today, 4/7/2026, According to Top Analysts - TipRanks.com

Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding

Ovid Therapeutics Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:OVID) 2026-03-19

Ovid Therapeutics (OVID) Q4 Earnings and Revenues Surpass Estimates

Niagen Bioscience (NAGE) Tops Q4 Earnings and Revenue Estimates

PTC Therapeutics (PTCT) Reports Q4 Loss, Misses Revenue Estimates

Ovid Therapeutics: Bullish Post-PIPE With Two Differentiated CNS Moonshots

Ovid’s KCC2 activator shows promising safety in early trial

Ovid Therapeutics shareholders approve increase in authorized shares and related proposals